

# Pain Management at Boston Medical Center

"Pain is whatever the experiencing person says it is, existing whenever he says it does." -*M.McCaffery*, 1968

#### Summary of Pain Management Policy at BMC

- Assessment of pain will be made upon admission (to hospital/clinic/unit), upon transfer, post-operatively, after significant change in patient condition, with change in caregiver and upon discharge.
- Document pain intensity using a 0-10 scale or the Wong-Baker FACES: 0=NO PAIN...10=WORST PAIN IMAGINABLE
- Surrogate descriptors will be used for nonverbal or preverbal patients.
- Develop an individualized pain management plan based on patient goals and functional status.
- Readjust plan as needed based on patient response to interventions.

#### Pain Management Medication Guidelines Always Consider:

- The *"type"* of pain, e.g. somatic vs. neuropathic
- Patient as a "unique individual" with specific physiological and psychosocial components of his/her pain experience
- Language, age, developmental/cognitive status, coping skills, cultural background/beliefs, availability of personal resources
- Drug properties vs. patient specific parameters that may affect drug metabolism, elimination, etc.

**General Considerations:** "Severity" of the pain should be considered first in developing analgesic regimen

- "Moderate-to-severe" pain: interferes with the patient performing activities of daily living (ADLs) or 5+ on a 0-10 scale suggests opioids should be initially considered, or current opioid dose increased, interval changed or opioid changed to a more effective type
- "Mild-to-moderate" pain, 0-5, usually responds to a mix of physical treatment modalities, NSAIDs, and/or adjuvant medications currently available. Opioids are appropriate in certain cases.
- "Acute/Intermittent" and "Chronic/Intermittent" pain may effectively controlled by short-acting opioids; however, "Acute/Continuous" and

"**Chronic/Continuous**" pain usually requires treatment that is "continuous" with long-acting, sustained-release, or ATC (around-the-clock) dosing.

**Goals of Pain Management:** Increase/maintain comfort, function & prevent/control side effects

*Non-Opioid Analgesics:* Additive effects with opioids may relieve pain so that higher doses of opioids are not required.

<u>Analgesics & Adjuvants:</u> Doses given below for pain relief are common starting/average doses. Please contact pharmacy for maximum dose information and with any questions or concerns regarding safe and effective dosing.

#### **Oral Analgesic Medications For Pain Relief**

Agent/Usual Dose:	Note:
Acetaminophen: 325-650mg	No anti-platelet/-inflammatory effects;
po q 4-6 hrs or 1000mg po q 6	additive analgesia when given with
	opioid; do not use in hepatic failure
Choline/magnesium salicylate:	Minimal platelet effects; use with
500-1500mg bid-tid	caution in renal failure & GI disease
Ibuprofen: 600-800mg po tid	Use cautiously, if at all, in renal or
	hepatic failure, ulcer disease, &
	patients on anticoagulants
Indomethacin: 25-50mg po	As above
bid- tid	
Naproxen sodium: 250-500mg	As above
bid-tid (max 1250mg/day)	

#### **Oral Adjuvant Medications For Pain Relief**

Oral Adjuvant Medications For Pain Relief		
Class/Agent	Use	Comment
Anticonvulsants	Neuropathic	<ul> <li>Monitor drug</li> </ul>
Gabapentin 100-300mg qd-	"shooting" or	levels of
tid	"burning" pain	carbamazepine
Carbamazepine 100-200mg		and phenytoin
bid		(need albumin to
Phenytoin 150-200mg bid		appropriately
		assess phenytoin
		level)
Antidepressants	Neuropathic pain	<ul> <li>Tricyclics have</li> </ul>
Tricyclics	Note: Both the	anti-cholinergic
Amitriptyline 10-25 mg qhs	anti-convulsants &	side effects
Nortriptyline 10-50mg qhs	tricyclic anti-	
Non-Tricyclics & SSRIs	depressants have	
Trazodone 50mg tid; qhs	been used with	<ul> <li>SSRIs may cause</li> </ul>
Paroxetine 20 mg qhs	some success in	sexual
Fluoxetine 20 mg qam	paroxysmal or	dysfunction,
	sudden onset pain	insomnia, sedation
Biphosphonates	Malignant bone	Monitor:
Pamidronate 90mg IV	pain	<ul> <li>BUN/Creatinine</li> </ul>
infusion q monthly		<ul> <li>Electrolytes</li> </ul>
Muscle relaxants	Spastic muscle	Use short-
Cyclobenzaprine 10mg tid	pain	term
Baclofen 10mg tid	*	Side-effects:
Tizanidine 4-8mg qd		sleepiness,
Diazepam 2-10mg bid-tid		orthostatic htn,
Clonazepam 0.5-1mg qd-bid		constipation,
		vomiting

For the complete pain management guideline or information on formulary products, please visit: www.internal.bmc.org/pharmacy

### **Opioid Analgesics: Equianalgesic Conversion**

Opioid	Parenteral	Oral
Morphine	10mg	30mg (chronic)
		60mg (acute)
Codeine	130mg	200mg
Hydromorphone	1.5mg	7.5mg
Meperidine*	75mg	300mg
Methadone	10mg	20mg
Oxycodone	N/A	20mg
Fentanyl	100mcg	N/A

\*Not a preferred drug. Meperidine should be used for:

- a. Treatment of acute episodes of moderate to severe pain in patient with a history of unmanageable adverse reactions or unsuccessful pain management with other opioid(s).
- b. Treatment prevention of rigors.
- c. Pre and post-procedure analgesia where rapid onset and short duration of drug action will improve patient care.
- d. Research protocols where meperidine is specified.
- e. Administration for neuraxial analgesia by anesthesia.

## Morphine/Duragesic<sup>TM</sup> Equivalency

Morphine Dose (mg) 24-hr. Parenteral dose	Fentany Patch (mcg/hr)
30	25
60	50
90	75
120	100
150	125
180	150
210	175
240	200
270	225
300	250
330	275
360	300

For Sustained-release products:

Oxycodone CR (OxyContin<sup>TM</sup>) 10mg = Morphine Sulfate CR (MS Contin<sup>TM</sup>) 20mg

<u>Conversions Between Opioids:</u> When converting between opioids/doses/administration routes the "must have" information is the original opioid, its total dose in 24 hours and its route.

**Incomplete cross-tolerance** exists between opioid(s). When switching from one opioid to another, dose re-Ductions should be considered if the patient has *stable*, *controlled pain*. Effective pain control may be achieved at 50-70% of the calculated equianalgesic dose.

# **Drug Allergies to Opioids**

- True allergies are rare
- Opioid Categories: Each is chemically distinct and therefore no cross-sensitivity exits between them.

Phenanthrenes:	Morphine, codeine,
(Morphine-Like Agonists)	hydrocodone, hydromorphone,
	levophanol, oxycodone
Phenylpiperidines:	Meperidine, fentanyl,
(Meperidine-Like Agonists)	alfentanil, sufentanil
Diphenylheptanes:	Methadone, propoxyphene,
(Methadone-Like Agonists)	diphenoxylate

## **Opioid Side Effects**

1. Dose-dependant, responding to a dose decrease of 25-50%

2. Occurs at initiation of opioid therapy, significant dose

increases and at peaks and troughs of opioid blood levels 3. Tolerance to side effects (except constipation) within days to weeks

<b>Common Side Effects:</b>	Less Common Side Effects:
Constipation	Urinary Retention
Sedation/Confusion	Delirium
Nausea & Vomiting	Seizures
Pruritis	Myoclonic Jerks
Respiratory Depression	

Respiratory Depression Management of Common Side Effects

# 1. Constipation

- Bowel regimen combining a stool softener and mild peristaltic stimulant for all patients:
- <u>Examples:</u> senna 187mg: 2 tabs qhs; docusate 100mg + casanthranol 30mg: 1 cap qd to 2 caps tid

## 2. Sedation/Confusion

- Eliminate non-essential CNS depressant medications
- Try lower opioid dose given more frequently to decrease peak concentrations
- Confusion without sedation: haloperidol 0.5-1 mg PO bid or tid OR consider changing opioid

## 3. Nausea/Vomiting

- Tolerance will develop with repeated administration
- Nausea with one drug does not mean nausea with all other opioids
- Switch agents and/or use antiemetic together
- Try promethazine 12.5-25 mg po q 4-6 h prn; if slowed GI motility: metoclopramide 10mg po tid-qid; if associated with motion/vertigo: scopalomine transdermal patch
- 4. **Pruritis:**
- Diphenhydramine 12.5-25mg IV or 25-50mg PO

# 5. Respiratory Depression

- Highest risk = opiate-naïve (and/or frail) elderly, infants, patients with pulmonary compromise
- Must be assessed on the basis of what is <u>normal</u> for that patient. If needed, stop opioid and refer to "Naloxone Use."

Naloxone Use: 0.1-0.2mg initially IV. Repeat doses of 0.4 to 2mg every 2-3 minutes to a total dose of 10mg. May be given IM or SC if IV route is not possible; also may be given down an endotracheal tube, using two times the IV dose. <u>Onset of reversal:</u> within 2 minutes if given IV, longer if SC or IM

<u>Peak effect:</u> 6-10 minutes; duration of action: 1-2 hours *Administer cautiously to patients who may have physical dependence to opioids.* Reversal will unmask pain symptoms & may precipitate an acute withdrawal syndrome.

# **Combination Products:**

- No maximum daily dose of an opioid alone BUT maximum daily dose of a combination product containing APAP or ASA. <u>Example:</u> Percocet 325/5mg = APAP 325mg and oxycodone 5mg (max APAP dose/day = 4000mg or 4grams)
- Opioid component often available as single, inexpensive form
- Expected benefit of the non-opioid component is usually available in a single OTC formulation
- Balance "convenience" of combination products vs dangers of individual component toxicities

**Breakthrough Pain:** Patients often have acute, "breakthrough" pain when on long acting sustained release opioids. Often immediate release (short acting) products are available of the same opioid as the long sustained-release opioid

## Calculating Breakthrough Doses:

ORAL OPIOIDS	PARENTERAL OPIOIDS
Identify 24-hr total dose &	Identify the hourly total dose &
administer 10-15% q1-2h	administer 25-50% q15-30min

Continuously evaluate escalating use of rescue doses as a potential indicator that the sustained-release dosing should be increased.

## Pain Consults: There are two main services.

 <u>The Pain Management Group (PMG)</u>: The PMG is concerned with the evaluation and treatment of acute and chronic pain. Page neurology consult resident for adult inpatient consults, otherwise call 638-8456 (ENC) or 414-5256 (MP).

Patients with the following conditions are appropriate for referral: Chronic back and neck pain; Chronic and acute headache; Neuropathic pain; Visceral and pelvic pain; Pain of unclear etiology which requires further evaluation; Pain unresponsive to conservative management; Pain requiring complex pharmacological management; Cancer and HIV related pain; Pain requiring evaluation for interventional and neuromodulatory management

#### <u>The Anesthesia Interventional Pain Management Center</u>: Appointments are made by calling 638-6965, Monday-Friday 8:30-5:00pm.

The most commonly performed interventional procedures are: Lumbar/Thoracic/Cervical Epidural Steroid Injections; Lumbar/Thoracic/Cervical selective nerve root blocks (diagnostic and therapeutic); Lumbar/Stellate ganglion blocks for sympathetic mediated pain/complex regional pain syndrome Type I (RSD); Trigger point injections with local anesthetic and/or steroid injection for myofascial pain syndrome (various muscle groups); Selective diagnostic/therapeutic peripheral nerve block with local anesthetic and/or steroids; Intravenous lidocaine infusion for various neuropathic pain syndromes; Celiac plexus block with local anesthetic for diagnostic/therapeutic purposes; Hypogastric plexus block with local anesthetic and/or steroid injection for diagnostic/therapeutic purposes; Placement of intrathecal catheter for infusion of narcotics/Baclofen (trial before permanent implant)

# Managing Pain in the Pediatric Population

"PainFree Measures by Protocol" when ordered by MD or NP allows the nurse to choose and administer pharmacologic and non-pharmacologic measures per the guideline below considering age, developmental level, type of procedure, and medication characteristics.

# PainFree Measures by Protocol:

1) <u>Sucrose</u>: 0.2-2cc (per gestational age) PO x1 dose given 2 minutes prior to procedure for patients up to 3 months of age.

**2) EMLA Cream:** apply to skin at least 1 hr before needlestick or circumcision per dosing guidelines for patients over 32 weeks gestation.

3) <u>ELA-Max Cream</u>: apply to skin at least 20-30 min prior to needlestick per dosing guidelines for patients 12 months and older.

**4)** <u>Numby Stuff</u>: 1cc of Iontocaine<sup>TM</sup> or lidocaine 2% with epinephrine 1:100,000 by iontopheresis prior to procedure for children over 1 year of age.

**5**) <u>Vapocoolant spray</u>: spray on skin (up to 10 seconds for Ethyl Chloride<sup>TM</sup>, FluoriMethane<sup>TM</sup>, or 2-3 seconds for Fluro-Ethyl<sup>TM</sup>) immediately prior to needlestick.

## PEDIATRIC ANALGESIC GUIDELINES

Acetaminophen 15 mg/kg/dose PO q4h or 20 mg/kg/ dose PR q6h (Max 75mg/kg/day or 4 grams/day) Choline magnesium trilisate 25mg/kg/dose PO a12 hours (Max 1500mg/dose)

**Codeine** 0.5-1 mg/kg/dose PO q4 hrs (**Max** 60mg/dose) **Ibuprofen** 10 mg/kg/dose PO q6 hrs (**Max** 800 mg/dose) **MS** Contin See conversion chart on reverse. For young patients, the usual safe dosing range= 0.3-0.6mg/kg/ dose PO Q12hr

Oxycodone 0.1-0.2 mg/kg/dose PO q4 hours (Max 10 mg/dose)

# PEDIATRIC SIDE EFFECT MANAGEMENT

Diphenhydramine 1 mg/kg/dose PO/IV q6 hours (Max 50mg/dose) Ondansetron < 10 kg=0.1 mg/kg/dose, ≥10kg = 1mg/ dose IV q8h (Max 1 mg/dose) Prochlorperazine if >2y of age, 0.1 mg/kg/dose PO/PR q6 hours (Max 10 mg/dose) Promethazine if >2y of age, 0.5 mg/kg/dose q4h (Max 25mg/dose)